The MiR-17-92 Cluster: Yin and Yang in Human Cancers
Overview
Affiliations
MicroRNAs (miRNAs) are non-coding RNAs which modulate gene expression via multiple post-transcriptional mechanisms. They are involved in a variety of biological processes, including cell proliferation, metastasis, metabolism, tumorigenesis, and apoptosis. Dysregulation of miRNA expression has been implicated in human cancers, and they may also serve as biomarkers of disease progression and prognosis. The miR-17-92 cluster is one of the most widely studied miRNA clusters, which was initially reported as an oncogene, but was later reported to exhibit tumour suppressive effects in some human cancers. This review summarizes the recent progress and context-dependant role of this cluster in various cancers. We summarize the known mechanisms which regulate miR-17-92 expression and molecular pathways that are in turn controlled by it. We discuss examples where it acts as an oncogene or a tumour suppressor along with key targets affecting hallmarks of cancer. We discuss how cellular contexts regulate the biological effects of miR-17-92. The plausible mechanisms of its paradoxical roles are explained, and mechanisms are described that may contribute to cell fate regulation by miR-17-92. Further, we discuss recently developed strategies to target miR-17-92 cluster in human cancers. MiR-17-92 may serve as a potential biomarker for prognosis and response to therapy as well as a target for cancer prevention and therapeutics.
Mitoregulin Promotes Cell Cycle Progression in Non-Small Cell Lung Cancer Cells.
Stein C, Linzer C, Heer C, Witmer N, Cochran J, Spitz D Int J Mol Sci. 2025; 26(5).
PMID: 40076565 PMC: 11899852. DOI: 10.3390/ijms26051939.
Jiang Z, Allkanjari M, Chung P, Tran H, Ghanbari-Azarnier R, Wang D Cancers (Basel). 2025; 17(5).
PMID: 40075567 PMC: 11898778. DOI: 10.3390/cancers17050720.
Deregulation of Exosomal miR-17, miR-20a and TGFBR2 in Head and Neck Cancer Patients.
Rizwan M, Mahjabeen I, Haris M, Qayyum F, Kayani M Technol Cancer Res Treat. 2025; 24:15330338251323314.
PMID: 39989256 PMC: 11848883. DOI: 10.1177/15330338251323314.
Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.
Anvari S, Nikbakht M, Vaezi M, Amini-Kafiabad S, Ahmadvand M Cancer Cell Int. 2024; 24(1):410.
PMID: 39702293 PMC: 11660508. DOI: 10.1186/s12935-024-03596-8.
Quevillon Huberdeau M, Meister G Pflugers Arch. 2024; 477(1):35-36.
PMID: 39661108 PMC: 11711248. DOI: 10.1007/s00424-024-03053-5.